Growth Inhibition of Re-Challenge B16 Melanoma Transplant by Conjugates of Melanogenesis Substrate and Magnetite Nanoparticles as the Basis for Developing Melanoma-Targeted Chemo-Thermo-Immunotherapy
Time schedules and results for tumor volumes, survival periods, and rates of mice treated by the Protocol number 1. (a) Protocols of Groups I, II, III, and IV. (b) Tumor volumes of re-challenge B16F1 melanoma on day 14. All data are presented as mean ± standard deviation. Tumor volumes of Group IV were significantly reduced compared with those of the control group () or Group I (). There were no significant interactions between drugs and AMF (). (c) Kaplan-Meier survival curve over a period of 60 days after tumor re-challenge in Protocol number 1.
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.